Receptor News and Research

RSS

New clinical trial investigates aspirin as part of new treatment for triple negative breast cancer

An innovative new study is trialing whether giving aspirin, commonly used as pain relief, alongside immunotherapy drug avelumab could improve its effectiveness for people affected by breast cancer.

17 Aug 2021

MGH researchers discover how triple-negative breast cancer can evade powerful drugs

Massachusetts General Hospital researchers have identified for the first time how a highly aggressive form of breast cancer can evade one of the most powerful and effective drugs used to treat it, reporting their findings in Cancer Discovery, a journal of the American Association for Cancer Research.

17 Aug 2021

Making the nanobody big again for Cryo-EM

Researchers describe the method that allows high-resolution structure determination of small proteins by single-particle cryo-EM using a Legobody.

17 Aug 2021

Data reinforces SAB-185’s potential to neutralize SARS-CoV-2 variants

A study, available on the pre-print server bioRxiv*, evaluated the neutralizing capacity of a fully human polyclonal antibody (SAB-185) against the Delta, Kappa, and Lambda variants using a lentiviral-based pseudovirus assay.

17 Aug 2021

How delta and kappa variants of SARS-CoV-2 evade the immune system

A new study, available on the bioRxiv* preprint server, describes the neutralizing ability of the monoclonal antibodies against the variants and the difference of the ACE2 binding affinity found in the variants.

17 Aug 2021

In Southeast Asia, robust immunity found up to 9 months after SARS-CoV-2 infection

Now, a new study posted to the bioRxiv* preprint server focuses on functional immune memory to SARS-CoV-2, up to nine months in a Southeast Asian cohort, in the absence of re-infection.

16 Aug 2021

Vaccinating previously infected induces more potent antibodies less susceptible to escape from SARS-CoV-2 variants

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is the causal agent of the coronavirus disease 2019 (COVID-19) pandemic, which has claimed more than 4.3 million lives worldwide. Even after implementing various measures, such as vaccination and social restrictions, SARS-CoV-2 and its variants of concern (VoC) leave the world's public health systems and economies in turmoil.

16 Aug 2021

Tool for defining new SARS-CoV-2 spike nucleotide sequences to Pango lineage sets

In a recent study, a group of researchers determined the degree to which Pango lineages are distinguishable using spike-only nucleotide sequences.

16 Aug 2021

Study identifies mechanism of resistance and presents a much-needed target for advanced leukemias

Too many "exhausted" T cells left in the wake of aggressive chemotherapy regimens for patients with advanced chronic lymphocytic leukemia (CLL) make it more challenging for chimeric antigen receptor (CAR) T cell therapy to do its job.

16 Aug 2021

Obtained SARS-CoV-2 immunity, naturally or via vaccination persists 12 months

In a research paper recently uploaded to the preprint server medRxiv* by Havervall et al. (August 12th, 2021), neutralizing antibody titers towards wild-type SARS-CoV-2 and several variants of concern in individuals having either been vaccinated or infected with mild COVID-19 one year earlier are assessed, finding a reduced neutralization capacity against some strains.

16 Aug 2021

Response to a third SARS-CoV-2 vaccine dose amongst immunocompromised

In a research paper recently uploaded to the preprint server medRxiv* by Schrezenmeier et al. (August 12th, 2021) the potential benefit of three vaccine doses in either a homogenous or heterogeneous dosing regimen amongst kidney transplant patients is assessed, finding that the search for viable vaccination approaches amongst these patients remains an urgent medical need.

16 Aug 2021

SARS-CoV-2 Spike may trigger production of antibodies that cross-react with human thrombopoietin to induce thrombocytopenia

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infected individuals often suffer from thrombocytopenia, a condition associated with low platelet counts. The cytokine thrombopoietin regulates platelet count. Previous studies have reported that thrombocytopenia can increase the coronavirus disease 2019 (COVID-19) mortality rate by about five times.

16 Aug 2021

Research suggests toll-like receptor 4 appears to play role in severe COVID

A group of researchers re-evaluated their previously proposed hypothesis, which stated that the TLR4 activated by the spike glycoprotein S1 domain increases ACE2 expression and, thereby, aids in COVID-19 infection.

16 Aug 2021

Role of neutrophil-epithelial interactions in SARS-CoV-2 infection

Researchers discuss the relationship between airway neutrophils and SARS-CoV-2 infection to determine the impact that neutrophils have on COVID-19.

15 Aug 2021

Certain intestinal bacteria induce cross-reactive IgA responses to the SARS-CoV-2 spike RBD

A new study finds that human gut bacteria can induce antibodies of the immunoglobulin A (IgA) subtype that cross-react with the SARS-CoV-2 spike RBD.

15 Aug 2021

L452R mutations may have triggered the emergence of several COVID-19 variants

Most of the recently risen coronavirus variants of interest or concern -- delta, kappa, epsilon, iota and lambda -- are universally carrying a mutation in amino acid L452 of the Spike protein that helps the virus bind to host cells.

13 Aug 2021

Researchers identify genetic program in fruit fly that protects neurons from degeneration

Researchers at the University of Bonn have identified a previously unknown genetic program in the fruit fly. The genetic material involved controls the development of the neurons while also protecting them from degeneration.

13 Aug 2021

Discovery of highly potent neutralizing monoclonal antibodies against SARS-CoV-2

A new study published in the journal Nature Communications has reported two neutralizing antibodies, namely, nCoVmab1 and nCoVmab2, which are potent against SARS-CoV-2.

13 Aug 2021

How replication and recombination contribute to emergence of SARS-CoV-2 variants

The coronavirus disease 2019 (COVID-19) pandemic has been caused by the rapid outbreak of a novel coronavirus, namely, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). SARS-CoV-2 was first reported in late December 2019 in Wuhan, China. Since then, the virus has already claimed more than 4.3 million lives worldwide.

13 Aug 2021

Camelid nanobody anti-SARS-CoV-2 drug candidates

In a research paper recently published in the journal eLife, researchers from several US institutions have developed a nanobody-based candidate drug that effectively prevents and suppresses severe SARS-CoV-2 infection in animals.

12 Aug 2021

Receptor News and Research

New clinical trial investigates aspirin as part of new treatment for triple negative breast cancer

MGH researchers discover how triple-negative breast cancer can evade powerful drugs

Making the nanobody big again for Cryo-EM

Data reinforces SAB-185’s potential to neutralize SARS-CoV-2 variants

How delta and kappa variants of SARS-CoV-2 evade the immune system

In Southeast Asia, robust immunity found up to 9 months after SARS-CoV-2 infection

Vaccinating previously infected induces more potent antibodies less susceptible to escape from SARS-CoV-2 variants

Tool for defining new SARS-CoV-2 spike nucleotide sequences to Pango lineage sets

Study identifies mechanism of resistance and presents a much-needed target for advanced leukemias

Obtained SARS-CoV-2 immunity, naturally or via vaccination persists 12 months

Response to a third SARS-CoV-2 vaccine dose amongst immunocompromised

SARS-CoV-2 Spike may trigger production of antibodies that cross-react with human thrombopoietin to induce thrombocytopenia

Research suggests toll-like receptor 4 appears to play role in severe COVID

Role of neutrophil-epithelial interactions in SARS-CoV-2 infection

Certain intestinal bacteria induce cross-reactive IgA responses to the SARS-CoV-2 spike RBD

L452R mutations may have triggered the emergence of several COVID-19 variants

Researchers identify genetic program in fruit fly that protects neurons from degeneration

Discovery of highly potent neutralizing monoclonal antibodies against SARS-CoV-2

How replication and recombination contribute to emergence of SARS-CoV-2 variants

Camelid nanobody anti-SARS-CoV-2 drug candidates

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News